Risk model-based lung cancer screening strategies, which select individuals based on personal risk, are more cost-effective than current recommendations based solely on age and smoking history, according to a study led by the Cancer Intervention and Surveillance Modeling Network (CISNET) Lung Working Group, which includes researchers from The University of Texas MD Anderson Cancer Center, Houston.
>Sotorasib (Lumakras) continues to demonstrate durable efficacy in non–small-cell lung cancer (NSCLC) with KRAS p.G12C mutation at 2-year follow-up of the phase 2 CodeBreaK 100 clinical trial.
The phase 3 CheckMate-816 trial establishes a new standard of care for resectable non–small-cell lung cancer (NSCLC): neoadjuvant nivolumab (Opdivo) plus chemotherapy.
Antibody–Drug Conjugate Shows Promising Activity in Patients with Advanced or Metastatic EGFR Mutation–Positive NSCLC
Patritumab deruxtecan (HER3-DxD), an investigational antibody–drug conjugate targeting the HER3 growth factor receptor, showed promising activity in patients with locally advanced or metastatic EGFR mutation–positive non–small-cell lung cancer (NSCLC) who had received previous EGFR tyrosine kinase inhibitor (TKI) therapy, according to interim results from a phase 1 dose-escalation and dose-expansion trial.
Dual EGFR targeting with amivantamab-vmjw (Rybrevant) plus lazertinib (Leclaza) led to durable responses in more than one-third of chemotherapy-naïve patients with EGFR-positive non–small-cell lung cancer (NSCLC) whose disease had progressed on osimertinib (Tagrisso) therapy, according to a cohort analysis of the CHRYSALIS trial.
Approximately 13% of patients with lung adenocarcinoma harbor the KRAS p.G12C mutation, which is associated with poor clinical outcomes.
Neoadjuvant Nivolumab plus Chemotherapy Significantly Improves Pathologic Complete Response in Patients with Resectable NSCLC
Neoadjuvant nivolumab (Opdivo) plus chemotherapy significantly improved pathologic complete response (pCR) rates versus chemotherapy alone in patients with resectable stage IB-IIIA non–small-cell lung cancer (NSCLC), according to final results from the CheckMate-816 clinical trial.
Kammi Fox-Kay, MSN, RN, AOCNS, ONN-CG(T); Cathy Simmons, RN, BSN, ONN-CG(T); Lauren Welch, MSN, NP-C, AOCNP
Educating patients about cancer- and treatment-related side effect management
Sexual orientation and assigned sex at birth are significant determinants in the utilization of lung cancer screening, according to an analysis from the Behavioral Risk Factor Surveillance System (BRFSS) 2018, a cross-sectional, nationally representative database, that looked at screening among lesbian, gay, bisexual, transgender (LGBT) populations.
Genomic analysis of lung cancer in women who have never smoked may reveal novel mutations and structural alterations.